PURPOSE Women have more adverse events (AEs) from chemotherapy than men, but few
studies have investigated sex differences in immune or targeted therapies. We examined …

Background Accumulated evidence supports the existence of sex-associated differences in
immune systems. Understanding the role of sex in immune-related adverse events (irAEs) is …

Background Clinician reporting of symptomatic adverse events (AEs) in phase I trials uses
the Common Terminology Criteria for Adverse Events (CTCAE). The utility of the patient …

Background Immunotherapy is emerging as the cornerstone for treatment of patients with
advanced cancer, but significant toxicity (immune-related adverse events [irAEs]) associated …

Purpose: We aimed to elucidate predictive factors for the development of immune-related
adverse events (ir aes) in patients receiving immunotherapies for the management of …

Importance Immune checkpoint inhibitors (ICIs) and radiation therapy (RT) are widely used
to treat various cancers, but little data are available to guide clinicians on ICI use …

Adverse event (AE)-related costs represent an important component of economic models for
cancer care. However, since previous studies mostly focused on specific AEs, treatments, or …

Despite the enthusiasm surrounding novel targeted agents and immunotherapies,
chemotherapy remains the mainstay treatment for most human malignancies, either alone or …

Systematic capture of the patient perspective can inform the development of new cancer
therapies. Patient-reported outcomes (PROs) are commonly included in cancer clinical trials; …

Background Immunotherapy (IO) agents can cause late-onset immune-related adverse
events (irAEs). In phase I trials, observation for dose-limiting toxicities (DLTs) is typically …